Immuron proposes up to 10% extra share-issue capacity
Cash issues under the proposed placement facility must be priced at not less than 75% of VWAP.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Immuron Limited (IMRN) has scheduled its 2026 annual general meeting for November 18, 2026, at 2:00 p.m. AEDT. Shareholders will consider the 2026 remuneration report, Dr. Jeannette Anne Joughin’s re-election, an additional placement facility, renewal of the Omnibus Incentive Plan, and Param Lally’s election as a non-executive director. The explanatory statement reports director support for Joughin’s re-election and the placement proposal, no recommendation on the remuneration report or plan renewal, and opposition to Lally’s election; the proxy form lists votes FOR the first four proposals and AGAINST the fifth.
If approved, the placement facility would permit issues of up to 10% of issued capital, calculated at the time of issue, during the 12 months after the meeting, in addition to the existing 15% capacity under Listing Rule 7.1. Immuron states it is not proposing an issue under the facility as of October 16, 2026. The proposed incentive-plan cap is 12.5% of issued share capital over a rolling three-year period; the current plan cap would be 5% if renewal fails. Proxy forms are due by 2:00 p.m. AEDT on November 16, 2026.
Filing Explained
If shareholders approve Resolution 3, Immuron gains authority—not an issuance—to sell ordinary shares for cash at no less than
Key Figures
Key Terms
10% Placement Facility regulatory
VWAP financial
Omnibus Incentive Plan financial
Performance Rights technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much additional placement capacity is Immuron seeking?
What cap would apply under Immuron’s proposed Omnibus Incentive Plan?
When is the IMRN annual meeting and when are proxy forms due?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2026
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published an announcement (the “Public Notices”) to the Australian Securities Exchange on October, 16 2026, titled:
| - | Notice of Annual General Meeting and Proxy Form |
A copy of the Public Notices is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Notice of Annual General Meeting and Proxy Form |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMURON LIMITED | ||
| Date: October, 16 2026 | ||
| By: | /s/ Olga Smejkalova | |
| Olga Smejkalova | ||
| Company Secretary | ||
3
Exhibit 99.1
IMMURON LIMITED
ACN 063 114 045
(ASX code: IMC, NASDAQ code: IMRN)
NOTICE OF 2026 ANNUAL GENERAL MEETING AND
EXPLANATORY STATEMENT
Date and Time of Meeting:
Wednesday, 18 November 2026 at 2:00 pm
AEDT
Place of Meeting:
The Offices of Acclime Australia
Suite 1, Level 3, 62 Lygon Street, Carlton South, Vic 3053
If Shareholders are unable to attend the Meeting in person, they are encouraged to return the proxy form to the Company in accordance with the instructions thereon. Returning the proxy form will not preclude a Shareholder from attending and voting at the Meeting.
| This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety. If you are in doubt as to how to vote on any of the Resolutions, you should seek advice from your accountant, solicitor or other professional adviser without delay. |
IMMURON LIMITED
ACN 063 114 045
Notice of 2026 Annual General Meeting
Notice is given that a general meeting of the shareholders of Immuron Limited ACN 063 114 045 (Company or Immuron) will be held at the Offices of Acclime Australia, Suite 1, Level 3, 62 Lygon Street, Carlton South, VIC 3053 on Wednesday, 18 November 2026 at 2:00 pm AEDT for the purpose of considering and if thought fit passing the resolutions as stated below.
Please note that additional information concerning the proposed resolutions is contained in the Explanatory Statement that accompanies and forms part of this Notice of Annual General Meeting. Voting Exclusions to some of the following resolutions appear below and are deemed to form part of this Notice.
Business of the Meeting
Financial statements and reports
To receive and consider the financial statements and the reports of the Directors and of the Auditors for the year ended 30 June 2026.
Resolution 1: Adoption of Remuneration Report
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That the Remuneration Report for the year ended 30 June 2026 as set out in the Company’s Annual Report for the year ended 30 June 2026 be adopted.”
Please note that section 250R(3) of the Corporations Act 2001 (Cth) provides that the vote on this resolution is advisory only and does not bind the Directors or the Company.
A voting exclusion statement in respect of this Resolution is set out below.
Resolution 2: Re-election of Director – Dr Jeannette Anne Joughin
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Dr Jeannette Anne Joughin as a Non-Executive Director of the Company, who pursuant to clause 13.3 of the Company’s Constitution is retiring by rotation and being eligible offers herself for re-election.”
Resolution 3: Approval of increased placement capacity
To consider and, if thought fit, to pass the following resolution as a special resolution:
“That pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the increase in the capacity of the Company to issue equity securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions stated in the Explanatory Statement which accompanies and forms part of this Notice of Meeting.”
A voting exclusion statement in respect of this Resolution is set out below.
2
Resolution 4: Renewal of Omnibus Incentive Plan
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That the Shareholders approve the Company’s Omnibus Incentive Plan for the purposes of ASX Listing Rule 7.2 Exception 13(b), section 200B, 200E and 259B(2) of the Corporations Act 2001, and for all other purposes, as laid before the meeting, a copy of which is available for inspection at the registered office of the Company (during normal business hours).”
A voting exclusion statement in respect of this Resolution is set out below.
Resolution 5: Election Of Non-Board Endorsed Director Candidate
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That pursuant to clause 13.3.(e) of the Company’s Constitution and for all other purposes, the members of the Company approve the election of Mr Param Lally, who has nominated himself for election, and being eligible, is elected as a Non-Executive Director of the Company.”
By order of the Board
 |
|
| Olga Smejkalova | |
| Company Secretary | |
| 16 October 2026 |
3
Voting Exclusion Statement
Corporations Act
Resolution 1 - The Company will disregard votes cast by a member of the Key Management Personnel details of whose remuneration are included in the Remuneration Report, or a closely related party of such a member, in contravention of section 250R or 250BD Corporations Act. Restrictions also apply to votes cast as proxy unless exceptions apply.
For the purposes of section 224 Corporations Act, the Company will not disregard a vote if:
| (a) | it is cast by a person as a proxy appointed in writing that specifies how the proxy is to vote on the proposed resolution; and |
| (b) | it is not cast on behalf of a related party or associate of a related party of the Company to whom the resolution would permit a financial benefit to be given or an associate of such a related party. |
Listing Rules
In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the resolution by or on behalf of:
| Resolution 3: Approval of increased placement capacity | (a) | if at the time the approval of Resolution 3 is sought the Company is proposing to make an issue of securities under rule 7.1A.2, any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company; or | |
| (b) | an associate of such a person. | ||
| Resolution 4: Renewal of | (a) | any person who is eligible to participate in the employee incentive scheme; or | |
| Omnibus Incentive Plan | |||
| (b) | an associate of such a person. |
However, this does not apply to a vote cast in favour of the Resolution by:
| (a) | a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or |
| (b) | the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or |
| (c) | a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: |
| (i) | the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and |
| (ii) | the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. |
4
VOTING ENTITLEMENT NOTICE
| 1. | Entitlement to vote |
For the purposes of the Meeting, the Company has determined that in accordance with regulation 7.11.37 of the Corporations Regulations, shares will be taken to be held by the persons registered as holders at 7:00pm AEDT on Monday, 16 November 2026. Accordingly, transfers registered after that time will be disregarded in determining entitlements to vote at the Meeting.
| 2. | Voting at the meeting |
You may vote by participating in the Meeting at the above-described venue or by appointing an attorney or corporate representative to participate in the Meeting and vote for you. Alternatively, Shareholders who are entitled to vote at the Meeting may vote by appointing a proxy to participate and vote on their behalf, using the Proxy Form accompanying this Notice of Meeting or by appointing a proxy online.
| (a) | Jointly held Shares |
If more than one Shareholder votes in respect of jointly held Shares, only the vote of the Shareholder whose name appears first in the share register will be counted whether the vote is given personally, by attorney or proxy.
| (b) | Voting in person |
Shareholders wishing to vote, or their attorneys or in the case of a Shareholder or proxy which is a corporation, corporate representatives, may attend the Meeting in person at the Offices of Acclime Australia, Suite 1, Level 3, 62 Lygon Street, Carlton South, VIC 3053 at 2:00 pm AEDT on Wednesday, 18 November 2026. It is suggested that participants attend 30 minutes prior to the time designated for the commencement of the Meeting, if possible, to register and to obtain a voting card.
| (c) | Voting by proxy |
Shareholders wishing to appoint a proxy to vote on their behalf at the Meeting must either complete and sign or validly authenticate the personalised Proxy Form which accompanies this Notice of Meeting or lodge their proxy online. A person appointed as a proxy may be an individual or a body corporate.
Completed Proxy Forms must be delivered to the Share Registry by 2.00 pm AEDT on Monday, 16 November 2026 in any of the following ways:
| (i) | By mail in the enclosed reply-paid envelope (or the self-addressed envelope, for Shareholders whose registered address is outside Australia) provided to the Share Registry: |
Boardroom Pty Limited
PO Box 3993
Sydney NSW 2001
| (ii) | By facsimile to Boardroom Pty Limited, on facsimile number +61 2 9279 0664. |
| (iii) | Online if you wish to appoint your proxy online, you should do so by visiting https://www.votingonline.com.au/imcagm2026 and following the instructions on that website. Online appointments of proxies must be completed by 2:00 pm AEDT on Monday, 16 November 2026. |
| (iv) | By Hand: |
Boardroom Pty Limited
Level 8, 210 George Street
Sydney NSW 2000
5
A proxy need not be a Shareholder.
If you appoint a proxy and subsequently wish to attend the meeting yourself, the proxy will retain your vote and you will be unable to vote yourself unless you notify the registrar of the revocation of your proxy appointment before the commencement of the Meeting.
If a proxy appointment is signed by a Shareholder but does not name the proxy or proxies in whose favour it is given, the Chairman will act as proxy.
You are entitled to appoint up to two proxies to participate in the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy you must specify the names of each proxy and the percentage of votes or number of securities for each proxy on the Proxy Form. Replacement Proxy Forms can also be obtained from the Share Registry.
If you hold Shares jointly with one or more other persons, in order for your proxy appointment to be valid, each of you must sign the Proxy Form.
| (d) | Undirected proxies |
If a Shareholder nominates the chairman of the Meeting as that Shareholder’s proxy, the person acting as chairman of the Meeting must act as proxy under the appointment in respect of any or all items of business to be considered at the Meeting.
If a proxy appointment is signed or validly authenticated by that Shareholder but does not name the proxy or proxies in whose favour it is given, the Chairman of the Meeting will act as proxy in respect of any or all items of business to be considered at the Meeting.
Proxy appointments in favour of the Chairman of the Meeting, the Company Secretary or any Director which do not contain a direction as to how to vote will be voted in favour of the resolution at the Meeting.
The Chairman intends to vote undirected proxies of which the chair is appointed as proxy in favour of resolutions 1 – 4 and AGAINST resolution 5.
| (e) | Voting by attorney |
If you wish to appoint an attorney to vote at the Meeting, the original or a certified copy of the power of attorney under which the attorney has been appointed must be received by the Share Registry no later than 2:00 pm AEDT on Monday, 16 November 2026 (or if the Meeting is adjourned or postponed, no later than 48 hours before the resumption of the Meeting in relation to the resumed part of the Meeting).
Any power of attorney granted by a Shareholder will, as between the Company and that Shareholder, continue in force and may be acted on, unless express notice in writing of its revocation or the death of the relevant Shareholder is lodged with the Company.
Your appointment of an attorney does not preclude you from logging in online and participating and voting at the Meeting. The appointment of your attorney is not revoked merely by your participation and taking part in the Meeting, but if you vote on a resolution, the attorney is not entitled to vote, and must not vote, as your attorney on that resolution.
| (f) | Voting by corporate representative |
To vote by corporate representative at the Meeting, a Shareholder or proxy who is a corporation should obtain a Certificate of Appointment of Corporate Representative from the Share Registry, complete and sign the form in accordance with the instructions on it. The completed appointment form should be lodged with the Share Registry before 2:00 pm AEDT on Monday, 16 November 2026.
The appointment of a representative may set out restrictions on the representative’s powers. The appointment must comply with section 250D of the Corporations Act.
The original Certificate of Appointment of Corporate Representative, a certified copy of the Certificate of Appointment of Corporate Representative, or a certificate of the body corporate evidencing the appointment of a representative is prima facie evidence of a representative having been appointed.
6
IMMURON LIMITED
ACN 063 114 045
Explanatory Statement
This Explanatory Statement has been prepared for the information of Shareholders in connection with the business to be conducted at the Annual General Meeting of Shareholders to be held at 2:00 pm AEDT on Wednesday, 18 November 2026 (Meeting).
| 1. | Accounts and Reports |
The Corporations Act requires the Company to provide before the Annual General Meeting, the Financial Report, Directors’ report (including the Remuneration Report) and the Auditor’s Report for the financial year ended 30 June 2026.
Shareholders will be offered the opportunity to discuss the Financial Report, Directors’ Report and Auditor’s Report at the Meeting. Copies of these reports can be found on the Company’s website www.immuron.com.au.
There is no requirement for Shareholders to approve the Financial Report, Directors’ Report and Auditor’s Report. Shareholders will be offered the following opportunities:
| (a) | discuss the Annual Report for the financial year ended 30 June 2026; | |
| (b) | ask questions or make comments on the management of the Company; and | |
| (c) | ask the auditor questions about the conduct of the audit and preparation and content of the Auditor’s Report. |
In addition to taking questions at the Annual General Meeting, written questions to the Chairman about the management of the Company, or to the Company’s auditor about:
| (a) | the preparation and content of the Auditor’s Report; |
| (b) | the conduct of the audit; |
| (c) | accounting policies adopted by the Company in relation to the preparation of the financial statements; and |
| (d) | the independence of the auditor in relation to the conduct of the audit, |
may be submitted no later than 5 business days before the Annual General Meeting to the Company Secretary at the Company’s registered office.
| 2. | Resolution 1: Adoption of Remuneration Report |
| 2.1 | Corporations Act |
Under the Corporations Act, listed entities are required to put to the vote a resolution that the Remuneration Report section of the Directors’ Report be adopted. This Remuneration Report can be found in the Company’s 2026 Annual Report. It sets out a range of matters relating to the remuneration of Directors, the Company Secretary and senior executives of the Company.
7
A vote on this resolution is advisory only and does not bind the Directors or the Company. A copy of the Company’s 2026 Annual Report can be found on its website at www.immuron.com.au.
The Corporations Act provides that:
| (a) | members of the Key Management Personnel whose remuneration details are included in the Remuneration Report (and any closely related party of those members) are not permitted to vote on a resolution to approve the Remuneration Report, and |
| (b) | if the vote to approve the Remuneration Report receives a “no” vote by at least 25% of the votes cast, this will constitute a “first strike”. |
The Company’s current “strike” count is zero. If a “first strike” was to occur at the 2026 Annual General Meeting:
| (c) | the Company’s subsequent Remuneration Report (in other words, the Company’s Remuneration Report to be included in the 2027 Annual Report) must include an explanation of the Board’s proposed action in response to a 2026 “no vote” or an explanation of why no action has been taken; and |
| (d) | if the Company’s subsequent (i.e. 2027) Remuneration Report also receives a “no vote” at the 2027 Annual General Meeting of at least 25% of the votes cast, then Shareholders at the 2027 Annual General Meeting will be asked to vote on whether or not the Company is to hold another general Shareholder’s meeting (within the following 90 days) to vote on a “spill resolution” under section 250V of the Corporations Act. |
| 2.2 | Board Recommendation |
As set out in the Notice of Meeting, any member of the Key Management Personnel whose remuneration details are included in the Remuneration Report, together with a closely related party of those members, are excluded from casting a vote on Resolution 1.
Accordingly, the Board abstains from making a recommendation in relation to Resolution 1. The Chairman intends to exercise all undirected proxies in favour of Resolution 1.
| 3. | Resolution 2: Re-Election of Director – Dr Jeannette Anne Joughin |
| 3.1 | Background |
Clause 13.3(b)(iv) of the Company’s Constitution provides that a Director who has been in office the longest since being elected last would stand for election or re-election.
8
Dr Jeannette Joughin was elected as a Non-Executive Director on 18 November 2024, being eligible, offers herself for re-election.
Dr Jeannette Anne Joughin: Non-Executive Director
| |
| Appointment date | 1 June 2024 |
| Qualifications | Dr Joughin holds a Bachelor of Science (Honours) and a PhD, Immunology from Monash University. |
| Experience | Dr. Joughin is an experienced biopharmaceutical and medical device leader with 20+ years’ experience locally and internationally. Her operational and leadership experience has been forged through conducting research at universities and holding clinical and commercial positions of increasing seniority in multi-national pharmaceutical companies, start-up environments in private and listed companies located in the USA, Europe and Australia, and as a Venture Partner working with local and global portfolio companies. |
| Other listed directorships | Argenica Therapeutics Limited – Non-Executive Director Vitrafy Life Sciences Ltd – Non-Executive Director |
| Special responsibilities | Member of the Remuneration and Nomination Committee |
|
3.2 | Board Recommendation |
The Directors (other than Dr Jeannette Anne Joughin) recommend that Shareholders vote in favour of this Resolution 2. The Chairman intends to exercise all undirected proxies in favour of Resolution 2.
| 4. | Resolution 3: Approval of increased placement capacity |
| 4.1 | Placement capacity |
ASX Listing Rule 7.1A enables eligible entities, after obtaining shareholder approval by special resolution at an annual general meeting, to issue equity securities up to 10% of its issued share capital through placements over a 12-month period after the annual general meeting (10% Placement Facility). The 10% Placement Facility is in addition to the Company’s 15% placement capacity under Listing Rule 7.1. This Resolution 3 seeks approval to allow the Board the flexibility to issue additional Shares if it so decided. The Board may decide not to issue any Shares pursuant to this Resolution 3.
An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of $300 million or less. The Company is an eligible entity. The Company is now seeking shareholder approval by way of a special resolution to have the ability to issue equity securities under the 10% Placement Facility.
9
The exact number of equity securities to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2.
If this Resolution 3 is not approved by shareholders, then the Company will not have the flexibility of an available additional 10% capacity to issue Shares under the 10% Placement Facility described in section 4 of the Explanatory Statement. The Company not having the 10% Placement Facility will have no effect on the Company’s existing Listing Rule 7.1 15% capacity.
| 4.2 | Description of Listing Rule 7.1A |
Any equity securities issued under the 10% Placement Facility (Placement Securities) must be in the same class as an existing quoted class of equity securities of the Company. The Company, as at the date of the Notice, has on issue one class of quoted equity securities, being ordinary shares (Shares).
Resolution 3 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).
Eligible entities which have obtained Shareholder approval at an annual general meeting may issue or agree to issue, during the 12-month period after the date of the annual general meeting, a number of Placement Securities calculated in accordance with the formula in Listing Rule 7.1A.2.
The effect of Resolution 3 will be to allow the Directors to issue the Placement Securities under Listing Rule 7.1A during the 10% Placement Period (as defined below) without using any of the Company’s 15% placement capacity under Listing Rule 7.1.
| 4.3 | Specific information required by Listing Rule 7.3A |
Pursuant to and in accordance with Listing Rule 7.3A, information is provided in relation to the approval of the 10% Placement Facility as follows:
| (a) | Period for which approval will be valid | |
| Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A is valid from the date of the annual general meeting at which the approval is obtained and expires on the earlier to occur of: |
| (i) | the date that is 12 months after the date of the annual general meeting at which the approval is obtained; |
| (ii) | the time and date of the Company’s next annual general meeting; or |
| (iii) | the time and date of the approval by shareholders of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking), or such longer period if allowed by ASX (10% Placement Period). |
10
| (b) | Minimum issue price |
If any Placement Securities are issued, the minimum price the Placement Securities will be issued for cash consideration, which is not less than 75% of the VWAP of equity securities in the same class calculated over the 15 trading days on which trades in that class were recorded immediately before:
| (i) | the date on which the price at which the Placement Securities are to be issued is agreed; or |
| (ii) | if the Placement Securities are not issued within 10 trading days of the date in paragraph (i) above, the date on which the Placement Securities are issued. |
The actual number of Placement Securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of Placement Securities in accordance with the formula prescribed in Listing Rule 7.1A.2.
| (c) | Maximum Number of Shares to be Issued: |
Listing Rule 7.1A.2 provides that an eligible entity which has obtained a 7.1A mandate may, during the period of the mandate, issue or agree to issue a number of equity securities (N) equal to the 10% Placement Facility, calculated in accordance with the following formula prescribed in Listing Rule 7.1A.2:
N = (A x D) – E
where:
A = is the number of shares on issue 12 months before the date of the issue or agreement:
| ● | plus the number of fully paid ordinary securities issued in the relevant period under an exception in Listing Rule 7.2 other than exception 9, 16 or 17, |
| ● | plus the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within Listing Rule 7.2 exception 9 where: |
| - | the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or |
| - | the issue of, or agreement to issue, the convertible securities was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or Listing Rule 7.4, |
| ● | plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within Listing Rule 7.2 exception 16 where: |
| - | the agreement was entered into before the commencement of the relevant period; or |
| - | the agreement or issue was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or Listing Rule 7.4, |
11
| ● | plus the number of any other fully paid ordinary securities issued in the relevant period with approval under Listing Rule 7.1 or Listing Rule 7.4, |
| ● | plus the number of partly paid ordinary securities that became fully paid in the relevant period, |
| ● | less the number of fully paid ordinary securities cancelled in the relevant period. |
(Note: “A” has the same meaning as in Listing Rule 7.1 when calculating the 15% capacity);
D = 10%;
E = the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the relevant period (being the 12-month period immediately preceding the date of the issue or agreement), where the issue or agreement has not been subsequently approved by holders of ordinary securities under Listing Rule 7.4;
| (d) | Purposes for which Placement Securities may be issued |
The Company may seek to issue the Placement Securities as cash consideration for the acquisition of new assets and/or other investments, or as cash for general working capital purposes.
The Company will comply with the disclosure obligations under Listing Rules 7.1A.4 and 3.10.3 upon issue of any Placement Securities.
| (e) | Effect on existing (non-participating) Shareholders |
If Resolution 3 is approved by Shareholders and the Company issues Placement Securities under the 10% Placement Facility, the existing Shareholders’ voting power in the Company will be diluted as shown in the table below. There is a risk that:
| (i) | the market price for the Company’s equity securities may be significantly lower on the date of the issue of the Placement Securities than on the date of the Annual General Meeting; and |
| (ii) | the Placement Securities may be issued at a price that is at a discount to the market price for the Company’s equity securities on the issue date. |
The below table is included for illustrative purposes and shows the potential dilution of existing Shareholders on the basis of the current market price of the Shares as at 30 September 2026 and the current number of Shares for variable “A” (above) calculated in accordance with the formula in Listing Rule 7.1A.2 as at the date of this Notice.
The table also shows:
| (i) | Two examples where variable ‘A’ has increased by 50% and 100%. Variable ‘A’ is based on the number of Shares the Company has on issue as at the date of this Notice of Meeting. The number of Shares on issue may increase as a result of issues of Shares that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing rule 7.1 that are approved at a future shareholders’ meeting; and |
12
| (ii) | Two examples where the issue price of the Shares has decreased by 50% and increased by 50% as against the current market price. |
The table has been prepared on the following assumptions:
| (i) | The Company issues the maximum number of Placement Securities available under the 10% Placement Facility. |
| (ii) | The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%. |
| (iii) | The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder’s holding at the date of the Annual General Meeting. |
| (iv) | The table shows only the effect of issues of Placement Securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1. |
| (v) | The issue of Placement Securities under the 10% Placement Facility consists only of Shares. |
| (vi) | The issue price is $0.040, being the closing price of the Shares on ASX on 30 September 2026. |
| Dilution Table | |||||
Number of Shares on Issue (Variable ‘A’ in Listing Rule 7.1A.2)* |
Shares issued – 10% voting dilution |
Issue Price (rounded down to nearest tenth of a cent) | |||
| $0.020 | $0.040 | $0.060 | |||
| 50% Decrease | Issue Price | 50% Increase | |||
| Funds Raised | |||||
| Current | 322,848,081 | 32,284,808 | $645,696 | $1,291,392 | $1,937,088 |
50% increase |
484,272,121 | 48,427,212 | $968,544 | $1,937,088 | $2,905,633 |
100% increase |
645,696,162 | 64,569,616 | $1,291,392 | $2,582,785 | $3,874,177 |
13
| (f) | Company’s share allocation policy |
The Company’s share allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the allottees of Placement Securities will be determined on a case-by-case basis having regard to the factors including but not limited to the following:
| (i) | the methods of raising funds that are available to the Company, including but not limited to, issues in which existing security holders can participate; |
| (ii) | the effect of the issue of the Placement Securities on the control of the Company; |
| (iii) | the financial situation and solvency of the Company; and |
| (iv) | advice from corporate, financial and broking advisers (if applicable). |
The allottees under the 10% Placement Facility have not been determined as at the date of this Notice of Meeting but may include existing substantial Shareholders and/or new Shareholders who are not related parties or associates of a related party of the Company.
| (g) | Information under ASX Listing Rule 7.3A.6 |
As at the date of this Notice, the Company has issued 26,821,997 equity securities under Listing Rule 7.1A.2 in the past 12 months preceding the date of the AGM. The issue of 26,821,997 fully paid ordinary shares were ratified at the General Meeting held on 12 February 2026.
| (h) | Voting exclusion statement |
A voting exclusion statement is provided above in this Notice. As at the date of this Notice the Company is not proposing to make an issue of equity securities under Listing Rule 7.1A.2.
| 4.4 | Recommendation |
The Directors of the Company believe that Resolution 3 is in the best interests of the Company and unanimously recommend that Shareholders vote in favour of Resolution 3. The Chairman intends to exercise all undirected proxies in favour of Resolution 3.
| 5. | Resolution 4: Approval of Omnibus Plan |
| 5.1. | Background |
The Board remains committed to incentivizing and retaining all the Company’s Directors, employees and consultants in a manner which promotes alignment of their interests with shareholder interests, whilst at the same time offering eligible participants market-competitive remuneration arrangements.
14
The Company desires to maintain maximum ability to raise capital in accordance with ASX Listing Rule 7.1, without seeking prior shareholder approval, and to have the flexibility to be able to issue a range of employee incentives, recognising that different types incentives may suit different employees at different times and under different circumstances. The Board has adopted one overall plan, an Omnibus Incentive Plan (Omnibus Plan or Plan), that will allow the Board the discretion to choose between offering eligible participants incentives referred to in that Plan, including options, shares, loan funded shares, performance rights, deferred shares and exempt shares.
Once approved, any securities issued pursuant to the Omnibus Plan will not reduce the Company’s capacity under Listing Rule 7.1.
A summary of the Omnibus Plan is set out in Annexure A to these Explanatory Notes, separated across Parts 1, 2, 3 and 4 of Annexure A.
The Directors abstain from making a recommendation on Resolution 4 as they are eligible to participate in the Omnibus Plan and therefore have a potential personal interest in the matter. The Chairman intends to vote undirected proxies in favour of this resolution.
If this Resolution 4 is approved by Shareholders, the Board will have greater discretion to issue additional equities under the Omnibus Plan to incentivise and retain Directors, employees and consultants with market-competitive remuneration arrangements in a manner which promotes alignment of their interests with shareholder interests. At the time of preparing this Notice, there are no plans to issue equities in addition to those set out in this Notice.
If this Resolution 4 is not approved by Shareholders, then the Company will still be able to issue securities under the Plan as approved by Shareholders on 21 November 2023, but subject to a cap in the Omnibus Plan on the maximum number of Shares that may be issued in a rolling 3 year period of 5% of the total issued Share capital, rather than the cap of 12.5% as proposed under this Resolution 4.
| 5.2. | ASX Listing Rules |
Listing Rule 7.1 requires shareholder approval for an issue of equity securities if, over a rolling 12-month period, the amount of equity securities issued (without prior shareholder approval) is or would be more than 15% of the number of ordinary shares on issue at the start of that 12-month period.
Listing Rule 7.2 exception 13(b) provides that an issue of securities under an employee incentive scheme does not detract from the available 15% limit under Listing Rule 7.1 if the issue of securities is made under an employee incentive scheme and that employee incentive scheme was approved by shareholders no more than three years before the date of issue of the Listing Rule 7.2, and this Resolution 4 seeks Shareholder approval for the Omnibus Plan to meet the 3-year approval requirement.
The Company intends that any issue of securities under the Omnibus Plan does not detract from the Company’s Listing Rule 7.1 15% entitlement. Accordingly, it is seeking Shareholder approval in order for the Company to be able to issue securities pursuant to the Omnibus Plan and have those securities qualify under exception 13(b) to Listing Rule 7.2.
15
| 5.3. | Information required for Listing Rule 7.2 Exception 13(b) |
Listing rule 7.2 Exception 13(b) requires the information detailed in sections (a), (b) and (c) below to be provided to members for approval under this resolution.
| (a) | Summary of Terms of Omnibus Plan |
A Summary of the terms of the Omnibus Plan appears in Part 1 of Annexure A, with further summaries of components of the Plan contained in Part 2, 3, and 4.
A full copy of the Omnibus Plan is available for inspection on the Company’s website at the following link: www.immuron.com.au/ and at the Company’s registered office.
| (b) | Number of Securities issued |
The Company has previously issued no securities pursuant to the Omnibus Plan.
8,000,000 options and 3,767,492 performance rights in total have been issued under the Company’s previous corresponding Employees’ Share and Option Plan (ESOP).
| (c) | The Maximum number of securities proposed to be issued under the Omnibus Plan (following the approval sought in Resolution 4) |
The aggregate number of securities (including Options) which may be issued under the ESOP, together with all securities which may be issued under all other employee incentive schemes, shall not at any time exceed 12.5% of the total number of issued Shares in the Company at the time of issue of the ESP Shares over a rolling 3-year period. At the time of preparing this Notice, 12.5% represented 40,356,010 equities.
| 5.4. | Termination benefits under the Omnibus Plan |
Section 200B of the Corporations Act requires shareholder approval by ordinary resolution, and in accordance with the special provisions of s 200E of the Act, in order to access the exemption from the prohibition on a company giving a person a benefit in connection with that person’s retirement from an office or position of employment in that company where that person is, or was in the three years prior to his or her retirement, in a managerial or executive office in that company.
The Omnibus Plan allows the Board, in its discretion, to accelerate vesting of share entitlements on a retirement, which could constitute a benefit otherwise prohibited under Section 200B. In order to give the Board flexibility to exercise its discretions under the Plan to the extent that an acceleration of vesting could be regarded as providing a person a benefit in connection with that person’s retirement from an office or position of employment (Employment Retirement Benefit), shareholder approval for the purposes of sections 200B and 200E of the Corporations Act 2001 is being sought.
16
For a section 200B benefit to be allowed, section 200E requires that this Notice of Meeting provide shareholders with either the value of the proposed benefits or, where the value of the proposed benefits cannot currently be ascertained, the manner in which the value of the proposed benefits is calculated, and the matters, events and circumstances that will, or are will likely to, affect the calculation of the value.
| (a) | Value of termination benefits |
The Board has not determined that it will exercise discretion to grant any Employment Retirement Benefits. In the circumstances of a possible Employment Retirement Benefit, the value of the benefits that the Board may give under the Omnibus Plan cannot be determined in advance, as many of the factors that will or are likely to affect that value and will not be known until the time the benefit is decided to be awarded (if at all).
Specifically, the value of Employment Retirement Benefits will depend on a number of factors,
| (b) | Further voting restrictions |
Insofar as Resolution 4 could relate to the provision of an Employment Retirement Benefit, in accordance with the Corporations Act, a vote on Resolution 4 must not be cast (in any capacity) by or on behalf of any person who may be entitled to receive a benefit in connection with that person’s retirement from a managerial or executive office in the Company (or any related body corporate), or an associate of that person. However, a person is entitled to cast a vote if:
| a) | it is cast by a person as a proxy appointed in writing that specifies how the proxy is to vote on the resolution; and |
| b) | it is not cast on behalf of that person or an associate of that person. |
As at the date of this Notice, the Board has not identified any particular person to receive a benefit in connection with that person’s retirement from a managerial or executive office in the Company.
| 5.5. | Loans for and security over Shares |
Section 259B(2) of the Corporations Act permits a Company to take security over its own shares issued pursuant to an employee share scheme under certain conditions, including where prior shareholder approval of the employee share scheme has been obtained. Accordingly, the Company is seeking shareholder approval under Resolution 4 in respect of the operation of section 259B(2) of the Corporations Act, for circumstances where the Company elects to provide an employee assistance in the acquisition of shares in itself, such as providing a loan for the exercise of Plan Options under the Omnibus Plan, and takes security over its own shares for repayment of the loan.
Section 260A of the Corporations Act allows only limited circumstances under which a company may provide financial assistance for the acquisition of shares in itself without obtaining prior shareholder approval, including pursuant to Section 260A(1) the giving of the assistance which does not materially prejudice
| (i) | the interests of the company or its shareholders, or |
| (ii) | the company’s ability to pay its creditors. |
17
The Board is of the view that Section 260A(1) exemption is applicable, and at the relevant times will be applicable, to any loans that may be granted for the exercise of Plan securities under the Omnibus Plan.
Accordingly, the Company will not be seeking shareholder approval with respect to Section 260A of the Corporations Act.
| 5.6. | Recommendation |
The Directors abstain from making a recommendation on Resolution 4 as they are eligible to participate in issues under the Omnibus Plan and therefore have a potential personal interest in the matter. The Chairman intends to vote undirected proxies in favour of this resolution.
| 6. | Resolution 5: Election of Non-Board Endorsed Director Candidate |
| 6.1 | Background |
Under clause 13.3(e) of the Company’s Constitution, no person other than a retiring Director or a Director vacating office under clause 13.1(c) is eligible for election as a Director at a general meeting unless a written notice nominating that person for election is received by the Company at least 35 Business Days before the meeting (or 30 Business Days before the meeting where the meeting has been requested by members).
Mr Lally validly nominated himself for election as a Director in accordance with the Company’s Constitution.
Mr Lally is a shareholder of the Company and has been assessed by the Board as being independent.
Mr Lally’s CV is attached to this Notice of meeting as Annexure B. The information regarding Mr Lally’s qualifications, skills and experience has been provided by Mr Lally and has not been independently verified by the Company.
The Board maintains a structured succession planning process to identify and assess potential Director candidates, having regard to the skills, experience, diversity and capabilities required to support the Company’s strategy and effective governance. The Board regularly reviews its composition to ensure it has an appropriate balance of skills, expertise and experience to discharge its responsibilities and act in the best interests of shareholders.
The Board carefully considers all Director nominations received, including shareholder-nominated candidates, against the current and anticipated needs of the Company, the Board Skills Matrix and the Board’s succession planning objectives.
Following consideration of Mr Lally’s nomination, the Board has concluded that Mr Lally’s appointment would not enhance the overall effectiveness of the Board at this time. In reaching this view, the Board considered the existing composition of the Board, the skills, expertise and experience currently represented on the Board, and the capabilities required to support the Company’s strategic priorities.
If this Resolution is passed, Mr Lally will be elected as a non-Executive Director of the Company. If this Resolution is not passed, Mr Lally will not be elected as a non-Executive Director.
Accordingly, the Board does not support Mr Lally’s election and recommends that shareholders vote AGAINST this Resolution.
18
| 6.2 | Board Recommendation |
The Directors recommend that Shareholders vote AGAINST this Resolution 5. The Chairman intends to exercise all undirected proxies AGAINST Resolution 5.
| 7. | Further information |
The Directors are not aware of any other information which is relevant to the consideration by members of the proposed Resolutions set out in this Notice of Meeting.
The Directors recommend members read this Explanatory Statement in full and, if desired, seek advice from their own independent financial or legal adviser as to the effect of the proposed resolutions before making any decision in relation to the proposed Resolutions.
Glossary Definitions
The following definitions are used in the Notice of Meeting and the Explanatory Statement:
Annual General Meeting / AGM means the annual general meeting of the Company to be held at the Offices of Acclime Australia, Suite 1, Level 3, 62 Lygon Street, Carlton South, VIC 3053.
ASIC means the Australian Securities & Investments Commission.
ASX means ASX Limited ACN 008 624 691.
ASX Listing Rules or Listing Rules means the Listing Rules of the ASX as amended from time to time.
ATM means at the market funding facility.
Board means the board of Directors of the Company.
Business Day means Monday to Friday inclusive, except New Year’s Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day
Chair means the chair of the Meeting.
Closely Related Party of a member of the Key Management Personnel means:
| a) | a spouse or child of the member; |
| b) | a child of the member’s spouse; | |
| c) | a dependent of the member or the member’s spouse; |
| d) | anyone else who is one of the member’s family and may be expected to influence the member, or be influenced by the member, in the member’s dealing with the entity; |
| e) | a company the member controls; or |
| f) | a person prescribed by the Corporations Regulations 2001 (Cth) for the purposes of the definition of ‘closely related party’ in the Corporations Act. |
19
Company means Immuron Limited ACN 063 114 045.
Constitution means the Company’s constitution.
Corporations Act or Act means the Corporations Act 2001 (Cth).
Director means a director of the Company.
Explanatory Statement means the explanatory Statement attached to this Notice.
Key Management Personnel or KMP means the key personnel as disclosed in the Remuneration Report.
Meeting means the annual general meeting subject to this Notice.
Notice of Meeting or Notice means this notice of Annual General Meeting.
Proxy Form means the proxy form accompanying the Notice.
Remuneration Report means the remuneration report of the Company for the year ended 30 June 2026 as set out in the Company’s Annual Report for the year ended 30 June 2026.
Resolution means the resolutions referred to in the Notice of Meeting. Share means a fully paid ordinary share in the capital of the Company. Share Registry means Boardroom Pty Limited.
Shareholder means a holder of a Share.
VWAP means volume weighted average price.
Annexure A - Omnibus Plan Summary
Part 1- General Omnibus Plan Terms
A summary of the terms of each of the constituent awards under the Omnibus Incentive Plan (Plan) is as follows:
Only those Employees, Directors and Contractors of the Company invited by the Board, in its absolute discretion, to apply for Awards will be eligible to participate (Eligible Participants).
Types of Award
The Plan Rules allow for the following Awards to be offered by the Board to Eligible Participants:
| (a) | a Loan Share, by which the Company may provide an Acquisition Loan in relation to Loan Shares by making a loan to a Participant on the terms set out in an Offer and in the Plan Rules - refer Part 2 below for further detail; | |
| (b) | an Option - a right to acquire a newly issued Share in the Company subject to achievement of specified vesting conditions and payment of the relevant exercise price - refer Part 3 below for further detail; | |
| (c) | a Performance Right to acquire a Share issued in the Company subject to achievement of the specific performance-based vesting conditions - refer Part 4 below for further detail; | |
| (d) | a Deferred Share Award, which are Shares issued to Eligible Participants: | |
| (i) | who elect to receive Shares in lieu of any wages, salary, director’s fees, or other remuneration; or |
20
| (ii) | by the Company in its discretion, in addition to their wages, salary and remuneration, or in lieu of any discretionary cash bonus or other incentive payment; or | |
| (e) | an Exempt Share Award may be offered, which are Shares issued for no consideration or at an Issue Price which is a discount to the Market Price with the intention that up to $1,000 (or such other amount which is exempted from tax under the Tax Act from time to time) of the total value or discount received by each Eligible Participant will be exempt from tax. |
Offer Letters
Awards will be issued to Eligible Participants that accept the terms of offer outlined in the letter of offer (Offer Letter). Participation in the Plan is voluntary. The Offer Letter will detail the following terms (where appropriate):
| (a) | Type of Award to be offered (e.g. Options, Performance rights, etc.); | |
| (b) | Number of Awards to be offered; | |
| (c) | Exercise period, which will include details of the vesting date or dates and the expiry date; | |
| (d) | Exercise price or issue price; | |
| (e) | Vesting performance conditions such as the achievement of a particular performance target; | |
| (f) | Vesting conditions, such as the requirement to remain a permanent employee; | |
| (g) | Disposal restrictions; | |
| (h) | Award expiry date, being the date that the terms of offer expire; and | |
| (i) | any other matters required to be specified in the Offer by either the Corporations Act or the Listing Rules. |
Exercising an Award
Exercising the Award is done by providing the Company with a Notice of Exercise stating the number of Award units to be exercised, and if required, accompanied by payment of the Exercise Price or acceptance of a loan agreement with the Company, to fund the Exercise Price.
Once a Participant has exercised a vested Award (including payment of the Exercise Price where required), the Company will issue new Shares to the Participant. If the Company has provided a loan to the Participant to fund the exercise price, the shares will be issued with disposal restrictions.
General Provisions
Generally, if the Eligible Participant ceased employment or engagement with the Company the below will apply. See Parts 1, 2 or 3 below for more detail:
| (a) | Unvested Options and Performance Rights lapse on the date of the date of cessation | |
| (b) | Upon cessation the Holder has 6 months to exercise your vested Options and/or Performance Rights, failing which vested Options and/or Performance Rights will lapse. | |
| (c) | outstanding loans by the Company (for the acquisition of Loan Plan Shares) are to be repaid within 30 days of cessation of employment. |
21
A Holder cannot vote in respect of Options and Performance Rights held under the Plan. Holders can vote in respect of Shares acquired under the Plan, including upon the exercise of vested Options and Performance Rights.
Subject to further detail contained in Parts 1, 2 or 3 below, in general:
| (a) | Options and Performance Rights | |
| (i) | may be subject to restrictions until they are exercised or expire. | |
| (ii) | may specify a Restriction Period for Shares issued on their exercise. | |
| (iii) | are subject to adjustment where there is a reorganisation of capital of the Company (other than by way of a bonus issue or issue for cash) to the extent necessary to comply with the Listing Rules as they apply at the relevant time (Reorganisation Adjustment). | |
| (b) | Loan Shares | |
| (i) | may be subject to restrictions until Vesting Conditions are satisfied and the Loan is repaid or satisfied; and | |
| (ii) | Loan and security terms apply. | |
| (c) | Deferred Share Awards | |
Unless a different Restriction Period is specified in an Offer, the Restriction Period for Deferred Share Awards will expire on the earlier of:
| (i) | when a Participant ceases to be an Eligible Participant; | |
| (ii) | when the Board, in its discretion, agrees to end the Restriction Period; and | |
| (iii) | 10 years from the date of issue of the Shares. | |
| (d) | Exempt Share Awards | |
Unless a different Restriction Period is specified in an Offer, the Restriction Period for Exempt Share Awards will expire on the earlier of:
| (i) | three years from the date of issue of the Shares; and | |
| (ii) | the time when a Participant ceases to be an Eligible Participant. | |
The Company will offer Exempt Share Awards on a non-discriminatory basis as defined by section 83A-35(6) of the Tax Act.
Dilution Limit
An Offer of Awards must not be made if the total of the following:
| (a) | the number of Shares which are the subject of the Offer of Awards; | |
| (b) | the total number of Shares which are the subject of any outstanding Offers of Awards; | |
| (c) | the total number of Shares issued during the previous five years under this Plan or any other employee share scheme extended only to Eligible Participants of the Company (adjusted if necessary in each case for capital reorganisations), but not including existing Shares transferred to a Participant after having been acquired for that purpose; and | |
| (d) | the total number of Shares which would be issued under all outstanding Awards that have been granted but which have not yet been exercised, terminated or expired, assuming all such Awards were exercised and ignoring any Vesting Conditions, |
22
but disregarding any Offer made, or Award offered or issued, or Share issued by way of or as a result of:
| (e) | an offer to a person situated outside Australia at the time of receipt of the offer; | |
| (f) | an offer that did not need disclosure to investors because of section 708 of the Corporations Act; or | |
| (g) | of offer made under a disclosure document as defined in the Corporations Act, would exceed 12.5% of the number of Shares on issue at the time of the Offer. |
Default Vesting Conditions
If vesting conditions or other vesting events are not specified in an Offer and the Offer does not expressly state to the effect that no vesting conditions apply, the following Vesting Conditions apply to any Options, Performance Rights or Loan Shares offered under the Plan:
| (a) | the Awards only vest if at the applicable vesting date the Participant either: | |
| (i) | remains employed with a Company Group Member, continues to provide consulting services to a Company Group Member or acts as a director of a Company Group Member (as applicable); or | |
| (ii) | ceased to do so before the applicable vesting date in circumstances where the person was a Good Leaver; and | |
| (b) | the Awards vest in equal one-third tranches on the first, second, and third anniversaries of the grant date of the Awards (or of another date specified in the Offer for this purpose). | |
Where, for the purposes of the Plan:
“Good Leaver” means a person who has ceased to be employed or engaged by the Company or its subsidiary as a result of that person’s:
| (a) | total or permanent disablement, or an illness which persists for at least 3 months, which in either case prevents the person from carrying out their previous functions as an employee, contractor or director; | |
| (b) | genuine redundancy; | |
| (c) | death; or | |
| (d) | other factors determined by the Board in its discretion to constitute sufficient reason to treat the person as a Good Leaver; |
provided that the Participant has not committed a material breach of their employment contract or obligations during their employment or engagement with the Company Group.
“Bad Leaver” means a person who has ceased to be employed or engaged by the Company or its subsidiary, in circumstances where they are not a Good Leaver.
Takeovers and control transactions
If a takeover bid is made to acquire all of the issued Shares of the Company, or a scheme of arrangement, selective capital reduction or other transaction is initiated which has an effect similar to a full takeover bid for Shares in the Company, then Participants are entitled to accept the takeover bid or participate in the other transaction in respect of all or part of their Awards, other than Exempt Share Awards, notwithstanding that a restriction period in respect of such Awards has not expired.
The Board may, in its discretion, waive unsatisfied vesting conditions in relation to some or all Awards in the event of such a takeover or other transaction.
23
Ranking
Shares allotted under or on the exercise of an Award will rank equally in all respects with the then existing issued ordinary fully paid shares in the capital of the Company (except to the extent any such Shares are subject to a restriction agreement upon issue or in respect to any dividends which shall have been declared but not yet distributed before the actual exercise of an Option) and will be subject to the provisions of the Constitution of the Company.
Reorganisation Event
If, prior to the exercise of an Award, the Company undergoes a reorganisation of capital (other than by way of a bonus issue or issue for cash) the terms of the Awards of the Participant will be changed to the extent necessary to comply with the Listing Rules as they apply at the relevant time.
Annexure A - Omnibus Plan Summary Part 2 - Loan Share Terms:
The Omnibus Plan empowers the Board to exercise its discretion to issue fully paid ordinary shares in the Company (Loan Shares) to employees who qualify to participate in the Plan, upon the basis that the Company advances (Loan) the Participant the funds to purchase the Loan Shares pursuant to the terms of a secured limited recourse loan agreement between the Participant and the Company (Loan Agreement) and that the Participant enters a Restriction Agreement with the Company. The Loan Shares may be issued subject to vesting conditions as determined by the Board in its discretion.
Loan Terms
The key terms of each limited recourse loan (Loan) provided under the Plan (Loan Terms) are as follows:
| (a) | the Loan may only be applied towards the subscription price for the Loan Shares; | |
| (b) | the Loan will be interest free, provided that if the Loan is not repaid by the repayment date set by the Board, the Loan will incur interest at 9% per annum after that date (which will accrue on a daily basis and compound annually on the then outstanding Loan balance); | |
| (c) | by signing and returning a limited recourse Loan application, the Participant acknowledges and agrees that the Loan Shares will not be transferred, encumbered, otherwise disposed of, or have a security interest granted over it, by or on behalf of the Participant, until the Loan is repaid in full to the Company; | |
| (d) | the Company has the discretion as to whether it will require the Participant to provide the Company with security over the Loan Shares as security for repayment of the Loan, which security includes a pledge of the Participant’s Loan Shares provided under the Plan and a charge over all dividends and other amounts paid or payable on those Loan Shares; | |
| (e) | the Participant is required to enter a restriction agreement with the Company (Restriction Agreement) in accordance with the terms of the Employee Share Plan; | |
| (f) | the Loan becomes repayable on the earliest of: | |
| (i) | 5 years from the date on which the Loan is advanced to the Participant; | |
| (ii) | one month after the date of (A) the Participant’s resignation or cessation of office/engagement/employment (as the case may be) (other than if the Participant is removed from office), (B) if the Company does not renew the Participant’s employment agreement or engagement terms, or (C) where the Company dismisses the Participant other than for cause; and | |
| (iii) | (by the legal personal representative of the Participant) six months after the Participant ceases to be an employee of the Company due to their death; |
24
the earliest date being the Repayment Date.
| (g) | notwithstanding paragraph (f) above, | |
| (i) | the Participant may repay all or part of the Loan at any time before the Repayment Date; and | |
| (ii) | the Loan will be limited recourse such that on the Repayment Date the repayment obligation under the limited recourse loan will be limited to the lesser of the outstanding balance of the limited recourse loan and the market value of the Loan Shares on that date. | |
| (h) | where the Participant has elected for the Loan Shares to be provided to the Company in full satisfaction of the Loan, the Company must accept a transfer of the Loan Shares by the Participant to, or as directed by the Company, as full settlement of the repayment obligation under the limited recourse loan. |
Rights attaching to the Loan Shares
The Loan Shares will rank equally with all other fully paid ordinary shares on issue in the capital of the Company, other than for the provisions of an applicable Restriction Agreement. Holders of Loan Shares will be entitled to exercise all voting rights attaching to those Shares in accordance with the Company’s constitution. In addition, holders of Loan Shares will be entitled to participate in dividends declared and paid by the Company in accordance with the Company’s constitution, but the Company may retain, or pay to itself on behalf of a Participant, any moneys (including dividends) and any capital distributions that may become payable in respect of a Loan Share in reduction of the amount outstanding under the Loan in respect of that Loan Share.
Sale of the Loan Shares
The Loan Shares may only be sold by a Participant (who has been granted a limited recourse loan) where the Loan Shares have vested and the Loan has been repaid in full (otherwise any dealing by the Participant in the Loan Shares is prohibited without the prior written consent of the Company).
If the Loan becomes due and payable under the Loan Agreement and the Participant has not repaid the amount of the Loan in full within 21 days of the due date, then the Participant will forfeit their interest in the Loan Shares as full consideration for the repayment of the outstanding Loan balance (other than any interest accrued and unpaid on any overdue loan repayment), and the Company may either (at its election) take such action in the Participant’s name or direct that the Participant take such action in relation to the Loan Shares as the Company considers appropriate, which may include but is not limited to the Company undertaking a buy-back of the Loan Shares or transferring or selling the Loan Shares. For the purpose of this sale, the Participant appoints the secretary of the Company (or his or her duly authorised delegate) as their attorney and authorises them to sell the relevant Loan Shares on behalf of the Participant. The Company and the secretary will have complete discretion in respect of the sale of the relevant Loan Shares.
Copies of the Employee Share Plan are available for inspection at the Company’s registered office and will be provided without charge to shareholders on request.
Application Form Terms
The Application for the Loan Shares to be executed by a Participant includes the appointment by the Participant of the Company to be its attorney under a power of attorney (Power of Attorney) to perform all acts required on the Participant’s behalf in order
| (a) | to transfer the shares (not yet vested) which are the subject of the Application to a nominee or nominees of the Company at the Issue Price per Share, or | |
| (b) | for the Company to undertake a buy back (at the Issue Price per Share) or capital reduction of those Shares not yet vested pursuant to the provisions of the Corporations Act 2001, |
25
upon the basis that the Application Form is an irrevocable direction to the Company to apply all proceeds that would have otherwise been provided or due to the Participant on a transfer, buy back or capital reduction solely in satisfaction of the Outstanding Loan Balance (as defined in the Loan Agreement).
The Application Form also contains a vesting condition that prevails over all other (if any) vesting conditions (Liquidity Event Vesting Condition), namely that all Loan Shares vest immediately upon the happening of a Liquidity Event (as defined). A “Liquidity Event” is defined as:
| (a) | where a bidder under a takeover offer (as defined in the Corporations Act) has acceptances for more than 50% of the ordinary shares in the Company and there are no unsatisfied conditions (or conditions that not been waived) under the bid, or |
| (b) | on shareholder approval being obtained for a scheme of arrangement (as defined in the Corporations Act) with respect to the assets or securities of the Company; or |
| (c) | completion under a contract of sale with a third party purchaser of all, or substantially all, of the assets and undertaking of the Company. |
Termination benefits under the Plan
The Plan allows the Board, in its discretion and subject to the Listing Rules, to accelerate vesting of share entitlements on a retirement, for which Shareholder approval has been obtained where such an acceleration could constitute a benefit otherwise prohibited under Section 200B of the Corporations Act.
Annexure A - Omnibus Plan Summary Part 3 - Option Terms and Conditions:
Particulars
Participation in the Plan is voluntary. The number of Options; the Options exercise price and expiry date, any vesting conditions and any applicable restrictions will be determined by the Board in its absolute discretion and will be communicated to any Eligible Participant by way of letter of offer (Offer Letter).
Exercise of Options
The Options may be exercised for part or all of the Options vested at a particular time by the Option Holder giving written notice, in the required form and specifying the number of Options to be exercised and the method of exercise (Notice of Exercise) to the Company at its registered office prior to the Expiry Date.
Options in the Plan may be exercised by either:
| (i) | payment in full of the respective exercise price of the Options being exercised; or | |
| (ii) | by use of the Cashless Exercise Facility described below. |
The Cashless Exercise Facility entitles a Participant to set-off the cash Exercise Price against the number of Shares which the Participant is entitled to receive upon exercise of the Participant’s Options. If a Participant elects to use the Cashless Exercise Facility, the Participant will only be issued that number of Shares (rounded down to the nearest whole number) as are equal in value to the difference between the total Exercise Price otherwise payable in cash for the Options on the Options being exercised and the then market value of the Shares at the time of exercise (determined as the volume weighted average prices at which Shares were traded on the ASX over the 5 ASX Business Days immediately preceding the exercise date), calculated in accordance with the following:
S = O x (MSP – EP) MSP
Where:
S = Number of Shares to be issued on exercise of the Options using the Cashless Exercise Facility.
26
O = Number of Options being exercised.
MSP = Market value of the Shares (calculated using the volume weighted average prices at which Shares were traded on the ASX over the 5 ASX Business Days immediately preceding the exercise date).
EP = (Cash) Option Exercise Price.
To the extent the Cashless Exercise Facility is not utilised, an exercise of any Options will require the full payment of such Exercise Price shall be made in cash for these Options being exercised, such payment to accompany the Notice of Exercise, and shall be made
| (a) | in cash or bank cheque, or | |
| (b) | in any other manner permitted in the discretion of the Board. |
Such Notice of Exercise shall be delivered to the Company at its principal business office or such other office as the Board may direct, and shall be in such form, containing such further provisions consistent with the provisions of the Plan, as the Committee may prescribe. No person exercising an Option shall have any of the rights of a holder of the shares underlying that Option until the date that such ordinary shares are issued following the exercise of such Option. No adjustment shall be made for cash dividends or other rights for which the record date is prior to the date of such issuance.
On receipt by the Company of the Notice of Exercise and payment of the Exercise Price, the Company must, as soon as practicable and if the Shares are listed on the ASX within the time period prescribed by the Listing Rules of the ASX (ASX Listing Rules):
| (a) | allot to the Option Holder one Share in the Company for each Option exercised by the Option Holder; | |
| (b) | cause to be despatched to the Option Holder the relevant acknowledgement of issue, a holding statement or share certificate (as applicable) as soon as is reasonably practicable detailing the issue of the relevant Share/s; and | |
| (c) | issue (if applicable) a new holding statement (or option certificate) for the balance of the Options that remain unexercised. | |
Transfers
The Options are not transferable and are subject all restrictions, if any, as described in the Offer Letter.
Termination of Employment
If an Eligible Participant’s employment with the Company or its subsidiaries ceases, then:
| (a) | If that employee is a Good Leaver: | |
| (i) | the employee may continue to hold their vested Options and may be able to exercise them on the occurrence of a future Exit Event, and | |
| (ii) | their unvested Options lapse on the date of their termination. | |
| (b) | If that employee is a Bad Leaver, then their vested and unvested Options lapse on the date of their termination, unless the Board, in its sole discretion, determines otherwise. |
Reorganisation
If any reorganisation (including consolidation, subdivision, reduction, return or cancellation) of the issued capital of the Company occurs before the expiry of any Options, the number of Options to which each Option Holder is entitled or the Exercise Price of their Options or both must be reorganised in accordance with the ASX Listing Rules applying to a reorganisation at the time of the reorganisation (which adjustment formula will apply even where the Company is not admitted to the ASX Official List).
27
Rights Entitlement
An Option does not confer the right to participate in new issues of capital offered to holders of Shares (Rights Entitlement) during the currency of the Options without exercising the Options. However, the Company will use reasonable endeavours to procure that for the purpose of determining Rights Entitlements to any such issue, the Option Holder is to receive prior notice from the Company of the pending closing or record date and time for the Option Holder to exercise the Options prior to that closing or record date in order to qualify for the participation in the Rights Entitlement.
The Options do not provide any entitlement to dividends paid to ordinary shareholders. The Options do not entitle the Option Holder to vote at any meeting of shareholders
Governing Laws
To the extent (if any) that any of these Option Terms and Conditions are inconsistent with or contrary to the ASX Listing Rules, the ASX Listing Rules provisions will prevail, and these Option Terms and Conditions are deemed to incorporate the relevant ASX Listing Rules provisions as an amendment to these terms.
These Terms and Conditions are governed by the laws of Victoria. The Company and the Option Holder submits to the non-exclusive jurisdiction of the courts of Victoria.
Annexure A - Omnibus Plan Summary Part 4 Performance Rights
The Plan allows Eligible Participants to be granted performance rights over fully paid ordinary shares in the capital of the Company (Performance Rights). Each Performance Right is a right to acquire one fully paid ordinary share (Shares) in the capital of the Company at $nil exercise price.
If the Board proposes to grant the Performance Rights to an Eligible Participant (or their Nominated Parties) (Invitation), it will do so subject to the Company achieving certain milestones (Milestones). The Milestones, the total $value conditionally allocated (at a fair market value per Share to be determined upon exercise), the terms of their exercise and their expiry date will be determined by the Board in its absolute discretion (Performance Rights Terms) and will be communicated to any Eligible Participant by way of letter of offer (Offer Letter).
An Eligible Participant is a Director, consultant or employee of the Company or a subsidiary thereof. The following is a summary of the key terms and conditions that apply to all Performance Rights:
Entitlements
A Performance Right does not confer upon the holder (Holder) the right to
| (a) | receive notices of general meetings and financial reports and accounts of the Company that are circulated to holders of fully paid ordinary shares in the capital of the Company (Members). | |
| (b) | vote or receive dividends. | |
| (c) | a return of capital, whether in a winding up, upon a reduction of capital or otherwise. | |
| (d) | participate in the surplus profit or assets of the Company upon a winding up; or | |
| (e) | participate in new issues of securities such as bonus issues or entitlement issues | |
unless and until the applicable performance milestone is achieved and the Performance Right converts into ordinary shares.
Share ranking
All Shares issued upon exercise of the Performance Rights will upon issue rank pari passu in all respects with all other Shares.
28
Transfer / transmission of Performance Rights
A Performance Right may not be transferred or encumbered. Unless, on the death or legal incapacity of the Holder, the relevant dealing is affected by force of law to the Holder’s legal personal representative or the Board otherwise determines, a Holder may not dispose of a Performance Right that has been granted to them. The Board may require that a Performance Right be forfeited if a disposal occurs or is purported to occur other than in accordance with these terms.
Participation in new issues
There are no participation rights or entitlements inherent in the Performance Rights and holders will not be entitled to participate in new issues of capital offered to Members during the currency of the Performance Rights.
Adjustment for Reorganisation
If any reorganisation (including consolidation, subdivision, reduction, return or cancellation) of the issued capital of the Company occurs before the expiry of any Performance Right, all rights of a holder of a Performance Right (including the exercise conditions) must be reorganised in accordance with the ASX Listing Rules applying to a reorganisation at the time of the reorganisation (which adjustment formula will apply even where the Company is not admitted to the ASX Official List).
Exercise of Performance Rights
The exercise of a Performance Right is to be affected by the Holder completing and returning an exercise notice which will be attached to the Holder’s Offer Letter (Exercise Notice). Each Performance Right confers upon the Holder the right to be issued a certain number of Shares (as set out in their Offer Letter) following the achievement of the milestones (also as set out in their Offer Letter) (Milestones). The fair market value of Shares to be issued will be as determined by the Board in good faith on such basis as it deems appropriate and applied consistently with respect to all Shares, or another pricing method determined by the Board as at the date the Company receives the Exercise
Notice.
Lapse if Milestone not achieved
If the relevant Milestone is not achieved by the due date as set out in the Offer Letter, then the corresponding Performance Rights will automatically lapse on non-satisfaction of the Milestone.
Holding Statement
The Company will issue the Holder with a new holding statement for any Share issued upon exercise of a Performance Right within 10 business days following exercise.
Continued service
A Holder’s entitlement to any Performance Rights in relation to Milestones that have not been met, ceases upon the date that is 3 months after the Holder ceases to be an Eligible Participant. For any Milestone met prior to the date of cessation of service, the Holder remains entitled to exercise the relevant Performance Rights and be issued Shares, regardless of whether the Holder remains an Eligible Participant at the time of exercise. In the event that a Holder is made redundant, their entitlement to Performance Rights (not yet exercised) will be considered at the discretion of the Board.
Control Events
Performance Rights issued to a Holder may be immediately exercised and Shares issued to the Holder at the total discretion of the Board if the Company announces its intention to sell all or substantially all of its business undertakings or assets or if a takeover offer is made for the shares in the Company (subject to that offer becoming unconditional).
Maximum Conversion
Under no circumstances will the Company issue any Performance Rights such that if the number of ordinary shares into which the performance rights will convert if the applicable milestones are achieved is greater than the number of ordinary shares in the Company on the date of issue of the Performance Rights. Where the Company has options or other convertible securities on issue, the Company cannot issue Performance Rights to the extent that the total number of ordinary shares that will be issued if the options are all exercised, the convertible securities are all converted and the applicable milestone is achieved is greater than the number of ordinary shares in the entity on the date of issue of the Performance Rights.
29
PARAM LALLY
A highly strategic, governance-focused executive leader and significant stakeholder in Immuron. Brings a robust track record of corporate governance, strategic capital allocation, and risk management as the current Chief Financial Officer at Challenger Services Group. Offers the Board a deeply aligned owner-operator mentality coupled with deep commercial acumen to rigorously evaluate expansion initiatives and maximise long-term value for all shareholders.
| ● | Capital Allocation & Strategic M&A: Extensive background in corporate M&A, business case formulation, capital structures, and securing major debt/equity funding commitments. | |
| ● | Financial Governance & Planning: Expert oversight of corporate finance frameworks, international statutory reporting, and asset management in complex, multi-jurisdictional environments. | |
| ● | Risk Management, Systems & Compliance: Strong history of safeguarding assets, navigating global tax regimes, and upgrading enterprise architectures ahead of major liquidity events. | |
| ● | Shareholder Alignment & Transparency: Uniquely positioned as a top stakeholder to champion strict accountability, financial discipline, and performance metrics on behalf of investors. |
EXECUTIVE EXPERIENCE
CHALLENGER SERVICES GROUP | Sydney, Australia - Privately owned corporate group - FY26 Revenue A$120m, 2,000+ employees
Chief Financial Officer (CFO)
| ● | Strategic Growth & M&A Execution: Successfully negotiated and integrated an acquisition and a major merger, driving revenue growth from A$62m to A$120m, with a projected A$160m for FY27. Currently finalising a second strategic acquisition. | |
| ● | Capital Raising & Debt Structuring: Successfully arranged A$70m in banking commitments from Top 3 Australian financial institutions to fund the acquisition of a Tier-1 competitor. | |
| ● | Commercial Stewardship & Profitability: Streamlined complex group reporting frameworks to optimise data visibility, directly enhancing project margins and operational profitability metrics |
SALUDA MEDICAL LTD | Sydney, Australia - Medical Technology Sector | Market Cap: circa A$100m
Finance Projects Implementation & Process Improvements Consultant
Retained to architect financial structures, global business processes, and commercial models during crucial product launches and preparation for international expansion.
| ● | Capital & Grant Procurement: Formulated a 10-year corporate plan, comprehensive business case, and commercialisation dossier that directly supported a US$125m capital raising and an A$100m Medical Research Future Fund (MRFF) grant. | |
| ● | Global Commercialisation Partnering: Acted as the core finance business partner to US Sales and Global Marketing teams, steering the financial framework for the international soft launch of the EVOKE system. | |
| ● | Listing Preparation & Systems Architecture: Reviewed global business processes ahead of a proposed NASDAQ listing; successfully deployed global payroll, procurement, asset management, and Workday Adaptive systems. | |
| ● | International Tax Governance: Managed initial cross-border corporate registrations and drove the compliant lodgement of US Federal and State corporate tax returns. |
SPOTLESS GROUP (Subsidiary of Downer EDI Ltd - ASX: DOW) | Sydney, Australia
ASX Top 100 Subsidiary | Parent Market Cap: circa A$4b
Senior Finance Professional – Public Sector Portfolios
| ● | Large-Scale Contract Governance: Maintained strict commercial and financial integrity over 14 complex Whole-of-Government agency contracts totalling A$250m in annual revenue. | |
| ● | Risk & Mitigation: Monitored delivery margins and sovereign regulatory adherence across high-stakes public sector frameworks. |
30
BROADSPECTRUM SERVICES (Subsidiary of Ventia Services Group Ltd - ASX: VNT) | Sydney, Australia - Infrastructure Services | Parent Market Cap: circa A$4.5b
Finance Business Partner
Served as the strategic finance partner directly advising the Board, Chief Executive, Company Secretary, General Counsel, and Divisional Heads.
| ● | Global Overhead Optimisation: Managed A$320m corporate overhead budget encompassing 30 corporate divisions, 1,100 personnel, and A$50m in capital tech portfolios. | |
| ● | International Team Leadership: Supervised and led a high-performing team of 200 finance professionals across three continents. |
WORLEY LTD (ASX: WOR) | Sydney, Australia - Global Engineering & Energy Services | Market Cap: circa A$4.5b
Finance Business Partner
Provided financial oversight and commercial guidance to the Board, Group CEO, Chief Information Officer, Legal, and Regional Managing Directors.
| ● | Global Financial Management: Directly governed A$450m in group overheads spanning 30 countries and approximately 1,500 personnel | |
| ● | International Mobilisation: Seconded to Houston, Texas, to spearhead high-value commercial contract negotiations and business mobilisation in North American market. |
ADDITIONAL CORPORATE HISTORY
| ● | AUSGRID | |
Prepared critical asset valuation, financial integrity reporting, and regulatory dossiers for IPART and NSW Treasury ahead of the State Government’s multi-billion-dollar divestment process. Managed financial controls for a retail base of 1.6 million customers.
| ● | MACQUARIE GROUP (ASX: MQG) | |
Maintained and audited a A$500m global project portfolio tracking framework, delivering performance reporting to Regional Heads and Project Managers across four continents.
| ● | BRAMBLES LIMITED (ASX: BXB) | |
Accountable for the tracking, governance, and audit integrity of A$1.6 billion in global fixed assets. Partnered with internal corporate tax teams and KKR consultants on the due diligence for an A$800m asset carve-out.
EDUCATION & PROFESSIONAL CREDENTIALS
| ● | Chartered Accountants Australia and New Zealand (CA ANZ) | Qualified Member | |
| ● | Institute of Chartered Accountants of India (ICAI) | Qualified Member | |
| ● | University of Technology Sydney (UTS) | Graduate Conversion Course – Accounting | |
| ● | Panjab University, India | Bachelor’s Degree – Commerce & Law |
31
All Correspondence to: Boardroom Pty Limited By Mail GPO Box 3993 Sydney NSW 2001 Australia +61 2 9290 9655 By Fax: www.boardroomlimited.com.au Online: (within Australia) 1300 737 760 By Phone : (outside Australia) +61 2 9290 9600 YOUR VOTE IS IMPORTANT For your proxy appointment to be effective it must be recorded before 2:00pm (AEDT) on Monday, 16 November 2026. BY SMARTPHONE TO APPOINT A PROXY ONLINE STEP 1: STEP 2: STEP 3: VISIT https://www.votingonline.com.au/imcagm2026 Enter your Postcode OR Country of Residence (if outside Australia) Enter your Voting Access Code (VAC): Scan QR Code using smartphone QR Reader App TO VOTE BY COMPLETING THE PROXY FORM STEP 1 : APPOINTMENT OF PROXY Indicate who you want to appoint as your Proxy . If you wish to appoint the Chairman of the Meeting as your proxy, mark the box . If you wish to appoint someone other than the Chairman of the Meeting as your proxy, please write the full name of that individual or body corporate . If you leave this section blank, or your named proxy does not attend the meeting, the Chairman of the Meeting will be your proxy . A proxy need not be a securityholder of the company . Do not write the name of the issuer company or the registered securityholder in the space . how to vote or the Chairman of the Meeting is your proxy . If you appoint the Chairman of the Meeting as your proxy or the Chairman of the Meeting is appointed as your proxy by default, but you do not mark a voting box for Resolution 1 by completing and submitting this Proxy Form, you will be expressly authorising the Chairman of the Meeting to exercise your proxy in respect of this Resolution, even though this Resolution is indirectly or directly connected with the remuneration of the KMP . Appointment of a Second Proxy You are entitled to appoint up to two proxies to attend the meeting and vote . If you wish to appoint a second proxy, an additional Proxy Form may be obtained by contacting the company’s securities registry or you may copy this form . To appoint a second proxy, you must : (a) complete two Proxy Forms . On each Proxy Form state the percentage of your voting rights or the number of securities applicable to that form . If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes . Fractions of votes will be disregarded . (b) return both forms together in the same envelope . STEP 3: SIGN THE FORM The form must be signed as follows: Individual: This form is to be signed by the securityholder. Joint Holding : where the holding is in more than one name, all the securityholders should sign. Power of Attorney: to sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it. Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director, who is also the Sole Company Secretary, this form should be signed by that person. Please indicate the office held by signing in the appropriate place. STEP 2 : VOTING DIRECTIONS TO YOUR PROXY To direct your proxy how to vote, mark one of the boxes opposite each item of business . All your securities will be voted in accordance with such a direction unless you indicate only a portion of securities are to be voted on any item by inserting the percentage or number that you wish to vote in the appropriate box or boxes . If you do not mark any of the boxes on a given item, your proxy may vote as he or she chooses . If you mark more than one box on an item for all your securities, your vote on that item will be invalid . STEP 4 : LODGEMENT Proxy forms (and any Power of Attorney under which it is signed) must be received no later than 48 hours before the commencement of the meeting, therefore before 2 : 00 pm (AEDT) on Monday, 16 November 2026 . Any Proxy Form received after that time will not be valid for the scheduled meeting . Proxy forms may be lodged using the enclosed Reply - Paid Envelope or: Proxy which is a Body Corporate Where a body corporate is appointed as your proxy, the representative of that body corporate attending the meeting must have provided an “Appointment of Corporate Representative” prior to the meeting . An Appointment of Corporate Representative form can be obtained from the company’s securities registry . Online By Fax By Mail https://www.votingonline.com.au/imcagm2026 + 61 2 9290 9655 Boardroom Pty Limited GPO Box 3993, Sydney NSW 2001 Australia Voting restrictions for KMP Please note that if you appoint a member of the Company’s key management personnel ( KMP ) (which includes each of the directors) or one of their closely related parties as your proxy, they will not be able to cast your votes on Resolution 1 unless you direct them In Person Boardroom Pty Limited Level 8, 210 George Street, Sydney NSW 2000 Australia
Immuron Limited ACN 063 114 045 Your Address This is your address as it appears on the company’s share register . If this is incorrect, please mark the box with an “X” and make the correction in the space to the left . Securityholders sponsored by a broker should advise their broker of any changes . Please note, you cannot change ownership of your securities using this form . PROXY FORM APPOINT A PROXY STEP 1 I/We being a member/s of Immuron Limited (Company) and entitled to attend and vote hereby appoint: the Chairman of the Meeting (mark box) OR if you are NOT appointing the Chairman of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered securityholder) you are appointing as your proxy below or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting as my/our proxy at the Annual General Meeting of the Company to be held in - person at the Offices of Acclime Australia, Suite 1 , Level 3 , 62 Lygon Street, Carlton South, VIC 3053 on Wednesday, 18 November 2026 at 2 : 00 pm (AEDT) and at any adjournment of that meeting, to act on my/our behalf and to vote in accordance with the following directions or if no directions have been given, as the proxy sees fit . The Chairman of the Meeting is authorised to exercise undirected proxies on remuneration related matters : If I/we have appointed the Chairman of the Meeting as my/our proxy or the Chairman of the Meeting becomes my/our proxy by default and I/we have not directed my/our proxy how to vote in respect of Resolution 1 , I/we expressly authorise the Chairman of the Meeting to exercise my/our proxy in respect of this Resolution, even though Resolution 1 is connected with the remuneration of a member of the key management personnel for the Company . The Chairman of the Meeting will vote all undirected proxies IN FAVOUR of Resolutions 1 – 4 and AGAINST Resolution 5 . If you wish to appoint the Chairman of the Meeting as your proxy with a direction to vote against, or to abstain from voting on an item, you must provide a direction by marking the 'Against' or 'Abstain' box opposite that resolution . VOTING DIRECTIONS * If you mark the Abstain box for a particular item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your vote will not be counted in calculating the required majority on a poll. STEP 2 Abstain* Against For Board Recommendation Board recommended items. The Board recommends shareholders vote FOR resolutions 1 to 4 inclusive. FOR Adoption of Remuneration Report Resolution 1 FOR Re - Election of Director – Dr Jeannette Anne Joughin Resolution 2 FOR Approval of increased placement capacity (Special Resolution) Resolution 3 FOR Renewal of Omnibus Incentive Plan Resolution 4 Abstain* Against For Board Recommendation Non - endorsed items. The Board recommends shareholders vote AGAINST resolution 5. AGAINST Election of Non - Board Endorsed Candidate – Mr Param Lally Resolution 5 SIGNATURE OF SECURITYHOLDERS This form must be signed to enable your directions to be implemented. STEP 3 Securityholder 3 Director / Company Secretary Securityholder 2 Director Individual or Securityholder 1 Sole Director and Sole Company Secretary Contact Name…………………………………………….... Contact Daytime Telephone………………………................................ Date / / 2026